Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Belmalip; Colemin; Denan; L-644128-000U; Lipex; Liponorm; Lipovas; Lodales; Medipo; MK-733; Pantok; Sinvacor; Sivastin; Synvinolin; Velastatin; Zocor; Zocord

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of South Carolina; Merck Sharp & Dohme
  • Developer Cystic Fibrosis Foundation Therapeutics; Medical University of South Carolina; Merck & Co; Merck Sharp & Dohme; Sahlgrenska University Hospital; University of Tokyo
  • Class Antihyperlipidaemics; Naphthalenes; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic cardiomyopathy; Hypercholesterolaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia; Low HDL cholesterol
  • No development reported Cystic fibrosis; Multiple sclerosis
  • Discontinued Alzheimer's disease; Bone resorption; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystic-fibrosis in USA (PO, Tablet)
  • 01 Mar 2017 University College London initiates the phase III MS-STAT2 trial for Multiple sclerosis in United Kingdom
  • 15 Mar 2016 Biomarkers information updated
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top